Senti Biosciences, Inc.

Senti Biosciences, Inc. is a gene circuit company specializing in developing cell and gene therapies engineered with gene circuits to reprogram cells with biological logic. Their synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy for acute myeloid leukemia (AML); SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy for hepatocellular carcinoma (HCC); and SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy for colorectal cancer (CRC).

Products

• Cell and gene therapies engineered with gene circuits